In the article by Iorizzo et al., entitled ‘Ciclopirox 8% HPCH nail lacquer in the treatment of mild-to-moderate onychomycosis: a randomized, double-blind amorolfine controlled study using a blinded evaluator’ [Skin Appendage Disord 2015;1:134-140, DOI: 10.1159/000441569], the following corrections need to be made:
1. The title should be amended to ‘Ciclopirox 8% HPCH nail lacquer in the treatment of mild-to-moderate onychomycosis: a randomized, amorolfine controlled study using a blinded evaluator’.
2. The text in table 1, p. 136, line 6, should read as follows:
Table 1.
Baseline characteristics of randomized patients
| P-3051 | Amorolfine 5% | |
|---|---|---|
| (n = 60) | (n = 60) | |
| Age, years | 51.45 ± 11.75 | 53.85 ± 12.21 |
| Gender | ||
| Male | 6 (10.0) | 10 (16.7) |
| Female | 54 (90.0) | 50 (83.3) |
| Caucasian | 60 (100) | 60 (100) |
| Weight, kg | 71.80 ± 12.70 | 73.20 ± 10.30 |
| Fungal species | ||
| Dermatophytes | 43 (71.7) | 47 (78.3) |
| Yeast | 12 (20.0) | 11 (18.3) |
| Nondermatophyte moulds | 5 (8.3) | 2 (3.4) |
| Number of toenails with clinical evidence of onychomycosis | 6.8 ± 2.0 | 7.5 ± 2.0 |
| Percentage of infected target nail area | 44.62 ± 12.93 | 46.20 ± 13.58 |
Data are the mean ± SD, or n (%).
3. The Acknowledgment on p. 139 should be amended to read as follows: ‘This project was funded by Polichem SA. Data management and the statistical analysis were carried out independently by Sintesi Research SRL, Milan, Italy.’